HC Wainwright Issues Positive Forecast for Satellos Bioscience (NASDAQ:MSLE) Stock Price

Satellos Bioscience (NASDAQ:MSLE) had its price target upped by research analysts at HC Wainwright from $11.00 to $18.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 100.45% from the company’s current price.

A number of other brokerages also recently issued reports on MSLE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Satellos Bioscience in a report on Monday, May 11th. Canaccord Genuity Group upgraded Satellos Bioscience to a “moderate buy” rating in a report on Thursday, May 21st. Cantor Fitzgerald initiated coverage on Satellos Bioscience in a research report on Wednesday, March 11th. They set an “overweight” rating on the stock. Guggenheim began coverage on Satellos Bioscience in a research note on Tuesday, April 28th. They set a “buy” rating and a $23.00 target price for the company. Finally, Leerink Partners began coverage on Satellos Bioscience in a report on Monday, April 6th. They issued an “outperform” rating and a $20.00 price target for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

Satellos Bioscience Stock Performance

Shares of NASDAQ:MSLE opened at $8.98 on Thursday. Satellos Bioscience has a 52 week low of $4.64 and a 52 week high of $13.39. The firm has a 50 day moving average price of $6.90. The stock has a market cap of $187.05 million, a P/E ratio of -5.61 and a beta of 1.53.

Satellos Bioscience (NASDAQ:MSLE) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02). As a group, research analysts expect that Satellos Bioscience will post -1.69 earnings per share for the current fiscal year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.